Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary tables. ERJ-02066-2018_Supplement
Supplementary figure E1. Effect of LAM subtype (TSC-LAM versus sporadic LAM) on the rate of change in FEV1 (FEV1 slope): the FEV1 slope was similar in the placebo group in both TSC and sporadic LAM patients. Both groups exhibited a significant beneficial response to treatment with sirolimus. ERJ-02066-2018_Figure_E1
Supplementary figure E2. Rate of change in FEV1 (FEV1 slope) after dividing the MILES cohort on the basis of bronchodilator responsiveness at baseline: the presence or absence of bronchodilator responsiveness had no impact on the FEV1 slope in the placebo patients. Both subgroups exhibited a significant beneficial response to treatment with sirolimus. ERJ-02066-2018_Figure_E2
Supplementary figure E3. Rate of change in FEV1 (FEV1 slope) after dividing the MILES cohort on the basis of baseline FEV1 (51 –70% versus ≤50%): baseline FEV1 did not impact subsequent rate of disease progression in the placebo group. Both subgroups exhibited a beneficial response to treatment with sirolimus. ERJ-02066-2018_Figure_E3